AI주식인사이트AI Stock Insight
B

헬릭스미스

084990KOSDAQ자연과학 및 공학 연구개발업

65.0 / 100

Reference Date: 2026-04-13

Financial Score22.5 / 40
News Sentiment12.5 / 25
Momentum20.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but Revenue is on a declining trend. Surged 49.0% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Helixms is a biotech company established in 1996, specializing in CDMO, clinical CRO, analytical CRO, and H&B (health and beauty) businesses. It operates a state-of-the-art GMP facility compliant with FDA and Korean regulatory standards, and leverages natural-derived material technologies to develop pharmaceuticals and B2B products. The company also focuses on cell and gene therapy production, with extensive experience in global clinical trials and regulatory compliance.

Number of Employees

44people

Average Salary

54.4M KRW

Score Calculation Basis

Detailed Financial Score

PER
—Industry Average 120.074.0Point
PBR
2.96Industry Average 3.824.0Point

In line with industry avg

ROE
-0.33Industry Average -32.113.5Point

Well below industry avg

Debt Ratio
0.62Industry Average 7.528.0Point

Half of industry avg (excellent)

Trend 2023~20253.0 / 10 points
Revenue Growth Rate
0.0 / 3

Avg ▼14.7% (2-year basis)

Operating Profit Growth Rate
3.0 / 3

Avg ▲47.0% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -15.2% (improving, 3yr)

Detailed News Sentiment

1 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position8.0Point

Near 52w high (95%, uptrend)

Current 9,090Won52-week high 9,42052-week low 2,300
1-month return6.0Point

1m +49.02% (strong rise)

Volume trend6.0Point

Volume increasing

Detailed Disclosure

4 totalPositive 0Neutral 4Negative 0
  • Neutral사외이사의선임ㆍ해임또는중도퇴임에관한신고2026-03-30
  • Neutral정기주주총회결과2026-03-30
  • Neutral사업보고서 (2025.12)2026-03-20
  • Neutral감사보고서제출2026-03-18